UBS analyst Kevin Caliendo lowered the firm’s price target on Accendra Health (ACH) to $3 from $4 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACH:
- Tighter CMS Coverage Rules Put Accendra Health’s Non-Invasive Ventilation Revenue and Liquidity at Risk
- Owens & Minor Earnings Call Flags Tough 2026
- Accendra Health Posts 2025 Results, Guides 2026 Outlook
- Accendra Health reports Q4 adjusted EPS 21c, consensus 22c
- Accendra Health sees FY26 revenue $2.55B-$2.65B, consensus $2.6B